कृपया अन्य खोज का प्रयास करें
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company’s pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer’s, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient’s immunological system to combat Alzheimer’s disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Henry C.W. Nisser | 52 | 2019 | Executive VP, General Counsel & Director |
Stephan Jackman | 46 | 2018 | CEO & Director |
William B. Horne | 55 | 2016 | Chairman of the Board |
Milton Charles Ault | 54 | 2016 | Founder & Vice Chairman |
Henry C. W. Nisser | 55 | 2019 | Executive VP, General Counsel & Director |
Terri Hunter | - | 2022 | Member of Scientific Advisory Board |
Jeffrey Oram | 56 | 2021 | Independent Director |
Andrew H. Woo | 60 | 2021 | Independent Director |
Mark Garland Gustafson | 64 | 2021 | Independent Director |
Eric M. McDade | - | - | Member of Scientific Advisory Board |
Lynne Fahey McGrath | 68 | 2021 | Independent Director |
Thomas M. Wisniewski | - | 2019 | Member of Scientific Advisory Board |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है